Drug-drug interactions - A preventable patient safety issue? [1]

British Journal of Clinical Pharmacology

Volumn 65, Issue 1, 2008, Pages 144-146

  Strandell, Johanna ^a   Bate, Andrew ^b   Lindquist, Marie ^b   Edwards, I Ralph ^b  

^a UPPSALA MONITORING CENTRE   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; CARBAMAZEPINE; CIMETIDINE; CLOZAPINE; DICLOFENAC; ERYTHROMYCIN; ETHINYLESTRADIOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; INSULIN; IRINOTECAN; LEVONORGESTREL; METHOTREXATE; METRONIDAZOLE; NELFINAVIR; PHENYTOIN; QUETIAPINE; RISPERIDONE; RITONAVIR; ROSIGLITAZONE; SAQUINAVIR; SIMVASTATIN; THEOPHYLLINE; TIPRANAVIR; UNINDEXED DRUG; WARFARIN;

BODY WEIGHT; CARDIOVASCULAR RISK; CONVULSION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG ERUPTION; DRUG INTERACTION; DRUG OVERDOSE; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERBILIRUBINEMIA; LETTER; LEUKOPENIA; MEDICAL EDUCATION; MEDICAL STUDENT; NAUSEA; PATIENT SAFETY; PERIPHERAL EDEMA; PRESCRIPTION; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROTHROMBIN TIME; RHABDOMYOLYSIS; SEPSIS; SIDE EFFECT; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; VOMITING; WORLD HEALTH ORGANIZATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG INTERACTIONS; HUMANS; RISK MANAGEMENT; SWEDEN;

EID: 37249000860     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02981.x     Document Type: Letter

References (10)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998 279 : 1200 5.
2. Quinn DI, Day RO. Clinically important drug interactions. In : Avery's Drug Treatment, eds Speight TM, Holford HG. Auckland : Adis International 1997 : 301 38.
3. Lindquist M, Edwards IR. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center. J Rheumatol 2001 28 : 1180 7.
4. Eiermann B, Laine K, Böttiger Y, Gustafsson LL, Molin B. From bench to bedside - developing a knowledge database about drug interactions to be used in computerized prescribing tools at point-of-care in Sweden and Finland. Basic Clin Pharmacol Toxicol 2005 97 (Suppl. 1 94 (no. 345).
5. Stockley's Interaction Alerts. Available at http://www.medicinescomplete. com/mc/alerts/current/index.htm The Pharmaceutical Press 2006 (last accessed: December 2006).
6. Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER). Available at http://www.fda.gov/medwatch/SAFETY//may04.htm 2004. Last accessed 14 February 2007.
7. Marceille JR, Goins JA, Soni R, Biery JC, Lee TA. Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin. Pharmacotherapy 2004 24 : 1317 22.
8. Aronson JK. Balanced prescribing. Br J Clin Pharmacol 2006 62 : 629 32.
9. Glassman PA, Simon B, Belperio P, Lanto A. Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care 2002 40 : 1161 71.
10. Chen YF, Avery AJ, Neil KE, Johnson C, Dewey ME, Stockley IH. Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf 2005 28 : 67 80.